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Affective symptoms as predictors of Alzheimer’s
disease in subjects with mild cognitive impairment:
a 10-year follow-up study
I. H. G. B. Ramakers1*, P. J. Visser1,2, P. Aalten1, A. Kester3, J. Jolles1 and F. R. J. Verhey1
1 Department of Psychiatry and Neuropsychology, School of Mental Health and Neuroscience, Maastricht University Medical Centre, Alzheimer
Centre Limburg, Maastricht, The Netherlands
2 Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands
3 Department of Statistics, Maastricht University Medical Centre, The Netherlands
Background. Affective symptoms are common in subjects with mild cognitive impairment (MCI), but there is
disagreement whether these symptoms are predictive for Alzheimer’s disease (AD). We investigated the predictive
accuracy of affective symptoms for AD during a follow-up study in subjects with MCI, and whether the predictive
accuracy was modified by age, the presence of amnestic MCI or the length of follow-up.
Method. Newly referred subjects (n=263) with MCI older than 55 years were selected from a memory clinic
and followed up after 2, 5 and 10 years. Predictors investigated were : symptoms of depression, anxiety, apathy and
sleeping problems.
Results. Affective symptoms were present in 50–70% of the subjects. The average follow-up period was 5.4 years
and 79 subjects (29%) developed AD. Sleeping problems were associated with a decreased risk for AD [odds ratio
(OR) 0.35, p<0.001]. Symptoms of depression (OR 0.61, p=0.059) and anxiety (OR 0.58, p=0.051) showed a trend in
the same direction. The OR of apathy for AD was 0.67 (p=0.14). Depression was associated with a decreased risk for
AD only in subjects without amnestic MCI, but not in subjects with amnestic MCI. Moreover, anxiety was related to
the risk for AD differently between subjects diagnosed with AD at the 5-year follow-up (OR 0.23) and subjects
diagnosed with AD at the 10-year follow-up (OR 1.7).
Conclusions. Affective symptoms are associated with a decreased risk for AD. The risk may be dependent on MCI
subtype or length of follow-up, but it does not depend on age.
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Introduction
Mild cognitive impairment (MCI) is a condition that
refers to cognitive impairment in subjects without de-
mentia. It has various causes, including Alzheimer’s
disease (AD) (Visser et al. 2006). It is important to
identify MCI subjects with prodromal AD, because if
disease-modifying drugs for AD become available,
these are likely be most effective in the early stage of
the disease. Possible predictors for AD are affective
symptoms, such as depression, anxiety and apathy
(Ownby et al. 2006). These symptoms are common in
subjects with MCI (Apostolova & Cummings, 2007),
but it is uncertain whether they can predict AD in this
population (Steffens et al. 2006). Depressive symptoms
were associated with an increased risk of developing
AD in some studies (Modrego & Ferrandez, 2004 ;
Gabryelewicz et al. 2007), and with a decreased risk
in others (Rozzini et al. 2005 ; Liu et al. 2007), while
most studies did not find a relationship between
depression and AD at all (Tierney et al. 1999 ; Visser
et al. 2000a, b ; Copeland et al. 2003 ; Korf et al. 2004 ;
Robert et al. 2006 ; Wang et al. 2006 ; Feldman et al.
2007 ; Palmer et al. 2007 ; Teng et al. 2007 ; Panza et al.
2008). Similarly, discrepant results have been reported
regarding the predictive accuracy of apathy and
anxiety for AD (Robert et al. 2006; Feldman et al. 2007;
Liu et al. 2007 ; Palmer et al. 2007 ; Teng et al. 2007).
These contradictory findings suggest that the
relationship between affective symptoms and AD
is modified by other factors which varied between
studies, but these factors have not yet been identified.
Statistically non-significant findings may be explained
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by a small sample size or a brief follow-up period.
The aim of the present study was to investigate the
predictive accuracy of affective symptoms for AD
in a large clinical cohort of subjects with MCI over a
10-year follow-up period. In addition, we examined
whether age, the presence of amnestic MCI or the
length of the follow-up period modified the relation-
ship between affective symptoms and AD. We
hypothesized that the association between affective
symptoms and AD would be strongest in elderly
subjects or in subjects with amnestic MCI, as these
subjects are more likely to develop AD (Visser et al.
2006 ; Visser & Verhey, 2007). We examined whether
the length of the follow-up period was a potential
effect modifier, because previous studies suggested
that the predictive accuracy of depression for
dementia might increase or decrease with the length
of follow-up period (Green et al. 2003 ; Ownby et al.
2006). Besides depression, anxiety and apathy, we
also investigated sleeping problems as a predictor
for AD. Sleeping problems are common in affective
disorders and previous studies found that these
problems may be predictive for cognitive decline or
dementia (Jelicic et al. 2002).
Method
Subjects
Subjects were selected from an ongoing longitudinal
study of non-demented subjects who had been
referred to the Maastricht Memory Clinic. The mem-
ory clinic is an out-patient clinic of the Maastricht
University hospital (Verhey et al. 1993). The design of
this study has been described in detail elsewhere
(Verhey et al. 1993 ; Visser et al. 2006). Consecutive
patients were included at the time of the first visit
to the memory clinic. Subjects included had to be
40 years or older and to have MCI, which was defined
as a score of 2 or 3 on the Global Deterioration Scale
(GDS; Reisberg et al. 1982). This broad definition
of MCI is consistent with that of other studies (Tierney
et al. 1996 ; Feldman & Jacova, 2005 ; Tabert et al. 2006).
This definition was used because subjects with AD in
the predementia stage often do not meet the more
strict criteria of MCI, such as the criteria for amnestic
MCI (Geslani et al. 2005 ; Storandt et al. 2006 ; Dickerson
et al. 2007 ; Visser & Verhey, 2007). Exclusion criteria
were : the existence of dementia at baseline, and
an apparent cause for the cognitive impairment, such
as cerebrovascular disorders, brain trauma, endocrine
disorders, or psychiatric disorders other than mild
affective disorders at baseline (Visser et al. 2000a).
For the present study we selected subjects older
than 55 years, who had been eligible for at least one
follow-up assessment (n=263). Subjects included
in this study were referred to the memory clinic
by general practitioners (72%), neurologists (4%),
psychiatrists (13%) or others (11%). The study was
approved by the medical ethics committee at the
Maastricht University hospital. After the study had
been explained to them, all the subjects gave their
written informed consent.
Clinical assessment at baseline and follow-up
At baseline, all subjects underwent a standardized
assessment, which included: a detailed history of the
subject ; a psychiatric, neurological, and physical
examination ; the Mini Mental State Examination
(MMSE; Folstein et al. 1975) ; the GDS (Reisberg et al.
1982) ; the 17-item version of the Hamilton Depression
Rating Scale (HAMD; Hamilton, 1960) ; the Blessed
Dementia Rating Scale (BDS; Blessed et al. 1968) ; and
appropriate laboratory tests ; a neuropsychological
assessment including tests for measuring learning
and memory, working memory, fluency, intelligence,
speed of information processing and executive func-
tioning ; and a computerized tomography (CT) or
magnetic resonance imaging (MRI) as described
elsewhere (Verhey et al. 1993).
At 2, 5 and 10 years after baseline, subjects were
invited to participate in a follow-up assessment.
Because subjects were continuously enrolled, not all
subjects had been in the study long enough to undergo
a follow-up assessment after 5 or 10 years. At the
time of our analyses, 263 subjects were eligible for the
2-year follow-up, 232 for the 5-year follow-up, and 133
for the 10-year follow-up. The follow-up assessment
included a standardized questionnaire about medical
history and cognitive complaints, the MMSE, GDS,
BDS, HAMD, and a neuropsychological assessment
comparable with the baseline assessment. Subjects
who refused to come for the follow-up assessment
were interviewed by telephone, using a standardized
questionnaire about medical history and cognitive
complaints, and the Telephone Interview for Cog-
nitive Status (Brandt et al. 1988). In this way a
diagnosis was made in 14 subjects.
Amnestic MCI was defined as a score of 1.5 stan-
dard deviations below the mean of a reference popu-
lation on the delayed recall measure of the Auditory
Verbal Learning Test (AVLT), after correction for
age, sex and education (Petersen et al. 1999; Van der
Elst et al. 2005). The amnestic MCI criteria also require
intact activities of daily living. This was oper-
ationalized as the absence of dementia and a score
below 4 on the GDS, which was part of the inclusion
criteria of the study, in accordance with previous
studies (Geslani et al. 2005).
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The diagnosis of dementia and AD was made
according to the Diagnostic and Statistical Manual
of Mental Disorders, 4th edition (DSM-IV) criteria
and National Institute of Neurological and
Communicative Disorders and Stroke (NINCDS)
and the Alzheimer’s Disease and Related Disorders
Association (ADRDA) criteria (NINCDS-ADRDA;
McKhann et al. 1984 ; APA, 1994). The diagnosis of
frontotemporal dementia was made according to the
Neary criteria (Neary et al. 1998). Vascular dementia
was diagnosed according to the National Institute
of Neurological Disorders and Stroke (NINDS) and
the Association Internationale pour la Recherche
et l’Enseignement en Neurosciences (AIREN) criteria
(NINDS-AIREN; Román et al. 1993). The diagnoses of
dementia and AD were made independently both by
a neuropsychiatrist and a neuropsychologist. Both
were blinded to the baseline results. Consensus
about the diagnoses was reached for all subjects.
Affective symptoms
In the present study we made use of the subscales
from the HAMD (Hamilton, 1960) for anxiety (items
9, 10, 11, 15 and 17), depression (items 1, 2, 3, 7 and 8),
sleeping problems (items 4, 5 and 6) (Shafer, 2006)
and apathy (items 7, 8 and 13) (Li et al. 2001).
Statistical analyses
Statistical analyses were performed using SPSS (version
11 for Mac OS X; SPSS Inc., USA). We dichotomized all
affective symptom scores. Symptoms were considered
to be clinically present if at least one item included in
a subscale was either 1 or higher for items scored
on a three-point scale, or was o2 for items scored on
a five-point scale. Group differences were analysed
using an independent t test or x2 test. Predictive accu-
racy was analysed using a discrete-time survival
analysis model and implemented using logistic
regression and an appropriately adjusted dataset
(Hosmer & Lemeshow, 1999). The outcome group
included all subjects with AD at follow-up. The refer-
ence group included subjects without dementia or
with non-AD dementia at follow-up. Analyses were
performed with and without adjustment for age, sex
and education. The difference in odds ratio (OR) for
AD between subjects diagnosed with AD at the 2-year,
5-year and 10-year follow-up was tested using the
discrete-time survival analysis model (Hosmer &
Lemeshow, 1999). We also investigated interactions
of affective symptoms with amnestic MCI, and
with age (younger or older than 70 years). In order to
investigate whether findings were influenced by the
inclusion of subjects with non-AD-type dementia in
the reference group, we repeated the analyses after
the exclusion of subjects with non-AD-type dementia.
Results
At baseline, 263 MCI subjects were included in
the study. Their baseline characteristics are listed
in Table 1. Symptoms of depression, anxiety and
sleeping problems were present in about 50% of the
subjects, and symptoms of apathy in about 70%
(Table 1).
Outcome at follow-up
At least one follow-up was available for 228 subjects
(87%). The number of subjects at each follow-up and
the reason for the absence of a follow-up are shown in
Fig. 1. Subjects without outcome at a follow-up for
which they had been eligible were similar to subjects
with outcome with regard to age, sex, education,
MMSE score, score on the delayed recall test, HAMD
score, BDS score, proportion of subjects with amnestic
MCI and GDS score.
At follow-up, 79 subjects had developed AD and 11
subjects had developed other types of dementia,
namely vascular dementia (n=6), frontotemporal
dementia (n=1), Parkinson’s dementia (n=3) and
primary progressive aphasia (n=1) (see Fig. 1). The
annualized conversion rate to AD was highest for the
first years of follow-up and decreased with longer
follow-up intervals (11% for the first 2 years, 4.2%
for years 3–5, and 3.0% for years 6–10). The average
follow-up length was 5.4 years. The baseline charac-
teristics according to outcome are listed in Table 1.
Subjects who converted to AD were about 5 years
older at baseline, were more often female, had lower
MMSE and AVLT delayed recall scores, more often
had amnestic MCI, and had higher BDS and
GDS scores compared with the subjects who did not
develop AD (Table 1).
Predictors for AD
Univariate analyses showed that the presence of
sleeping problems [OR 0.43, 95% confidence interval
(CI) 0.26–0.71, p=0.001] and symptoms of apathy
(OR 0.58, 95% CI 0.35–0.96, p=0.034) were associated
with a decreased risk for AD. Depressive symptoms
(OR 0.62, 95% CI 0.38–1.03, p=0.065) showed a trend
in the same direction.
After adjustment for age, sex and education, sleep-
ing problems were associated with a lower risk for
AD (OR 0.35, 95% CI 0.20–0.62, p<0.001) (Table 2).
Symptoms of depression (OR 0.61, 95% CI 0.36–1.01,
p=0.059) and anxiety (OR 0.58, 95% CI 0.34–1.0,
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p=0.051) showed a trend in the same direction
(Table 2). After the exclusion of subjects who devel-
oped a non-AD-type dementia, results remained
essentially the same. Also impairment on individual
sleeping items was associated with a lower risk
of developing AD (sleep initiation : OR 0.30, 95%
CI 0.15–0.59, p<0.001; sleep continuation : OR 0.28,
95% CI 0.14–0.58, p=0.001 ; early awakening: OR
0.35, 95% CI 0.17–0.70, p=0.003).
Effect of amnestic MCI and age
The presence of amnestic MCI modified the relation-
ship between depressive symptoms and the risk
for AD (p=0.017). Depression was associated with
a lower risk for AD in subjects without amnestic
MCI (OR 0.34, 95% CI 0.13–0.93, p=0.036), but not in
subjects with amnestic MCI (OR 1.1, 95% CI 0.50–2.3,
p=0.85). Age did not modify the risk for AD for any
symptom.
Effect of length of follow-up period
We noted some differences in predictive accuracy
related to time of follow-up (Table 2), but these dif-
ferences were small. Only with regard to anxiety was
the risk of developing AD statistically significantly
different (p=0.046) in the case of subjects diagnosed
with AD at the 5-year follow-up (OR 0.23, 95% CI
0.08–0.66, p=0.007) and subjects newly diagnosed
with AD at the 10-year follow-up (OR 1.7, 95% CI
0.32–9.01, p=0.539).
Discussion
The major finding of this clinical, long-term follow-up
study is that sleeping problems were associated with
a decreased risk for AD. In addition, symptoms of
depression and anxiety also showed a trend in this
direction. The predictive accuracy of depression
was dependent on the presence of amnestic MCI and
that of anxiety on the length of follow-up period.
Previous studies on the predictive accuracy of
affective symptoms for AD in subjects with MCI
mainly focused on depressive symptoms. The out-
comes of our study are consistent with some of
these studies (Rozzini et al. 2005; Liu et al. 2007), but
in disagreement with others (Modrego & Ferrandez,
2004 ; Gabryelewicz et al. 2007). We found that
depressive symptoms were only associated with a
reduced risk in subjects without amnestic MCI. This
corroborates our earlier finding that in the absence of
moderately severe memory impairment, depression is
more likely to be associated with primary depression
than with prodromal AD (Visser et al. 2000b). It is








Mean age (S.D.) 66.9 (7.7) 64.2 (7.4) 69.8 (6.8) 65.8 (5.1) 0.000
Older than 70 years, % 36 25 46 180 0.003
Sex, % female 44 39 54 27 0.024
Education, % low, middle and high 23/46/31 19/50/31 23/45/32 18/46/36 0.747
Mean MMSE (S.D.) 27.6 (2.1) 28.3 (1.6) 26.3 (2.3) 27.7 (1.6) 0.000
Mean AVLT-delayed recall (S.D.) 6.0 (3.8) 7.7 (3.2) 2.8 (2.5) 7.6 (2.1) 0.000
Amnestic MCI, % 42 22 77 18 0.000
Mean HAMD – total score (S.D.) 9.0 (6.2) 9.1 (6.4) 7.7 (5.7) 10.6 (6.0) 0.110
Major depression, % 21 22 13 18 0.124
Mean BDS – total score (S.D.) 1.8 (1.8) 1.3 (1.4) 1.9 (1.6) 3.3 (4.0) 0.004
Mean GDS – total score (S.D.) 2.5 (0.5) 2.3 (0.5) 2.7 (0.5) 2.6 (0.5) 0.000
Affective symptoms, %
Depression 53 56 43 64 0.078
Anxiety 54 54 50 50 0.583
Apathy 65 68 53 73 0.038
Sleeping problems 50 56 37 27 0.008
AD, Alzheimer’s disease ; S.D., standard deviation ; MMSE, Mini Mental State Examination ; AVLT, Auditory Verbal Learning
Test ; MCI, mild cognitive impairment ; HAMD, Hamilton Depression Rating Scale ; BDS, Blessed Dementia Rating Scale ; GDS,
Global Deterioration Scale.
a Not demented v. AD.
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also in line with the observation that depressed sub-
jects without a plasma biomarker profile suggestive
of AD have better memory performances than
depressed subjects with such a profile (Sun et al. 2008).
We did not find that the predictive accuracy of
depressive symptoms for AD was dependent on
follow-up length, although population-based studies
did show that the risk of developing AD for those
with depressive symptoms either increased or
decreased with follow-up length (Green et al. 2003 ;
Ownby et al. 2006).
Anxiety was found to be associated with a
decreased risk for AD in two other studies as well
(Robert et al. 2006; Liu et al. 2007) ; but a population-
based study reached the opposite conclusion
(Palmer et al. 2007). These conflicting findings may
be explained by a difference in setting. Our findings
suggested that anxiety is associated with a decreased
risk in the short term and an increased risk in
the long term. This may indicate that the predictive
accuracy of anxiety for AD is dependent on the length
of follow-up period.
Unlike our study, previous studies reported that
apathy was associated with an increased risk for
AD, although this reached statistical significance in
only one study (Robert et al. 2006 ; Feldman et al.
2007 ; Teng et al. 2007). These conflicting findings
may have resulted from different ways of assessing
these symptoms, as we used a subscale from the
HAMD, while other studies used the informant-based
Neuropsychiatric Inventory (Cummings et al. 1994).
Sleeping problems have not been investigated be-
fore as predictors for AD in subjects with MCI. While
it is well known that sleep disturbances occur in mild
and moderate phases of AD, the present data show
that they are not associated with an increased risk
of developing AD in subjects with MCI, but, on the
contrary, with a decreased risk. This effect was seen
for all aspects of sleeping problems (sleep initiation,




(n = 263) 
35 no 2-year follow-up: 
•  9 Deceased 
•  18 Refusal    
•  6 Untraceable    





•  49 AD  








(n = 63) 
14 Demented:  
•  10 AD  
•  4 other dementia   
Not demented 
(n = 49)
66 no 10-year follow-up: 
•  56 Baseline less  
    than 10 years ago  
•  6 Deceased 
•  3 Refusal 
•  1 Other  
26 Demented: 
•  20 AD 
•  6 other dementia 
Not demented
(n = 125)
34 no 5-year follow-up:  
•  21 Baseline less  
   than 5 years ago  
•  3 Deceased 
•  3 Refusal 
•  5 Untraceable 
•  2 Other 
2 
Fig. 1. Flowchart of the follow-up. AD, Alzheimer’s disease.
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to our findings, a previous study conducted on the
general population showed that sleeping problems
were associated with cognitive decline (Jelicic et al.
2002). However, other studies did not find this
association (Foley et al. 2001 ; Tworoger et al. 2006).
Age did not modify the relationship between
affective symptoms and AD, although we expected
that affective symptoms would be associated with an
increased risk for AD in elderly subjects. It is possible
that the age range in our study was not large enough
to detect such an interaction.
A number of factors that have not been investigated
in the present study may explain the conflicting results
between studies. First of all, as we already mentioned
above, predictive accuracy may depend on whether
the study is conducted in a community or in a clinical
setting. For example, in a memory clinic setting
affective symptoms are always related to a memory
problem, which is not the case in a community setting.
Moreover, subjects seen in a clinical setting have gone
through a referral process. In our study, subjects had
been referred by a general practitioner or another
specialist and this may have led to an enrichment of
the sample by subjects with primary depression,
which would explain the high prevalence of depress-
ive symptoms and the decreased risk of affective
symptoms for AD. Second, predictive accuracy may
depend on the type of rating scale used. Like most of
the other studies, we used a clinician-based rating
scale for affective symptoms. Using a self-rating
scale for depression and anxiety (Arrindell & Ettema,
1981, 2003) would have yielded similar results
(data not shown). Also if we had used a diagnosis
of major depression as predictor, we would have
obtained similar results (OR 0.58, 95% CI 0.29–1.2,
p=0.13). Third, the variability between the studies
may be explained by differences in the presence of
vascular disorders or vascular risk factors, because
these factors may modify the relationship between
depression and cognitive impairment (Alexopoulos,
2006). Fourth, the variability may have resulted
from an interaction between age, MCI type, the
length of the follow-up period, setting, vascular risk
factors and diagnostic instruments. Finally, it is also
possible that the conflicting findings reflect random
variation.
The annual conversion ratio of 11% for the first 2
years is comparable with the mean annual conversion
rate of 10.2% found in a meta-analysis (Bruscoli &
Lovestone, 2004). The annual conversion ratio in our
study declined with the length of follow-up period, as
described before (Visser et al. 2006).
Few subjects developed non-AD types of dementia,
which is in line with other clinical MCI studies
(Geslani et al. 2005). After exclusion of subjects with
non-AD types of dementia, results remained similar,
which indicates that the inclusion of subjects with a
non-AD-type dementia in the reference group did not
affect the results.
The strengths of the present study were : the large
sample size ; the long follow-up period of up to 10
years ; the high follow-up rate ; and the broad inclusion
criteria for MCI in which mild depressive symptoma-
tology was not excluded at baseline, in accordance
with current recommendations (Steffens et al. 2006).
The limitations of the study were: the relatively small
number of subjects with a 10-year follow-up, and the
lack of pathological confirmation of the clinical diag-
nosis. In addition, a few diagnoses were based on a
telephone interview, which is less reliable than a
clinical and neuropsychological assessment. However,
post hoc analyses in which these subjects were ex-
cluded remained essentially the same (data not
shown), indicating that this did not introduce a major
bias.
There have been several hypotheses regarding the
relationship between depression, MCI and AD
(Steffens et al. 2006 ; Wilson et al. 2008). One hypothesis
proposes that depressive symptoms contribute to the
development of AD. A second hypothesis suggests
that depressive symptoms may be an early manifes-
tation of AD. A third hypothesis states that cognitive
Table 2. ORs of affective symptoms for ADa
Symptom
AD at any follow-up AD at 2-year follow-up AD at 5-year follow-up AD at 10-year follow-up
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
Depression 0.61 (0.36–1.01) 0.059 0.67 (0.34–1.31) 0.239 0.58 (0.21–1.56) 0.277 0.43 (0.10–1.76) 0.239
Anxiety 0.58 (0.34–1.0) 0.051 0.72 (0.36–1.45) 0.36 0.23 (0.08–0.66) 0.007 1.7 (0.32–9.01) 0.539
Apathy 0.67 (0.40–1.13) 0.136 0.61 (0.31–1.20) 0.153 0.76 (0.28–2.07) 0.589 0.79 (0.19–3.32) 0.75
Sleeping problems 0.35 (0.20–0.62) <0.001 0.28 (0.14–0.59) 0.001 0.37 (0.14–1.03) 0.057 0.87 (0.19–3.95) 0.853
OR, Odds ratio ; AD, Alzheimer’s disease ; CI, confidence interval.
a All data are corrected for age, education and sex.
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impairment results from a primary depressive dis-
order. Our data support the last hypothesis, as we
found that affective symptoms were generally asso-
ciated with a decreased risk for AD.
The present study indicates that affective symptoms
in subjects with MCI are not predictive for prodromal
AD. Given the high prevalence of affective symptoms
in prodromal AD (37–53%), however, the presence
of these symptoms certainly does not exclude the
possibility of prodromal AD. Therefore, the presence
of mild affective symptoms should not be an exclusion
criterion for studies that aim to select these subjects,
as has been the case in previous MCI trials (Visser
et al. 2005). It might be the case that in specific
samples affective symptoms are indeed associated
with an increased risk for AD, and that apart from
the type of MCI other factors that characterize such
samples remain to be identified. Because affective
symptoms are common in subjects with MCI, services
for subjects with cognitive complaints should pay
attention to this symptomatology, and should have
psychiatric expertise available to diagnose and treat
these symptoms.
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